Cargando…
Targeted Delivery of Epidermal Growth Factor to the Human Placenta to Treat Fetal Growth Restriction
Placental dysfunction is the underlying cause of pregnancy complications such as fetal growth restriction (FGR) and pre-eclampsia. No therapies are available to treat a poorly functioning placenta, primarily due to the risks of adverse side effects in both the mother and the fetus resulting from sys...
Autores principales: | Renshall, Lewis J., Beards, Frances, Evangelinos, Angelos, Greenwood, Susan L., Brownbill, Paul, Stevens, Adam, Sibley, Colin P., Aplin, John D., Johnstone, Edward D., Teesalu, Tambet, Harris, Lynda K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618188/ https://www.ncbi.nlm.nih.gov/pubmed/34834193 http://dx.doi.org/10.3390/pharmaceutics13111778 |
Ejemplares similares
-
Dysregulated flow-mediated vasodilatation in the human placenta in fetal growth restriction
por: Jones, Sarah, et al.
Publicado: (2015) -
Sildenafil Citrate Increases Fetal Weight in a Mouse Model of Fetal Growth Restriction with a Normal Vascular Phenotype
por: Dilworth, Mark Robert, et al.
Publicado: (2013) -
Melatonin Increases Fetal Weight in Wild-Type Mice but Not in Mouse Models of Fetal Growth Restriction
por: Renshall, Lewis J., et al.
Publicado: (2018) -
The impact of a human IGF-II analog ([Leu(27)]IGF-II) on fetal growth in a mouse model of fetal growth restriction
por: Charnock, Jayne C., et al.
Publicado: (2015) -
Tumor-homing peptides as tools for targeted delivery of payloads to the placenta
por: King, Anna, et al.
Publicado: (2016)